Asian Journal of Pediatric Research

Circulating fetoplacental nucleic acids have transformed prenatal medicine within a single generation, and screening based on cell-free DNA (cfDNA) is now offered routinely in many health systems. The field is moving quickly from the detection of whole-chromosome aneuploidy towards earlier sampling, sub-chromosomal resolution, monogenic diagnosis and the interrogation of epigenetic marks, yet the evidence supporting these extensions is uneven and the downstream consequences for children are rarely examined. This critical narrative review evaluates the state of knowledge on early prenatal detection of fetal genetic variants and epigenetic alterations through maternal blood sampling, and appraises the paediatric implications of an expanding prenatal detection frontier. Literature was identified through structured searching of Europe PMC and MEDLINE, Crossref Metadata Search, OpenAlex, Semantic Scholar and targeted retrieval of professional society statements, supplemented by backward and forward citation tracking. Evidence was appraised for design adequacy, confirmatory testing, spectrum of enrolled participants, and separation of analytical from clinical validity. Three findings dominate the synthesis. First, diagnostic confidence declines sharply and predictably as the target moves from common autosomal trisomies to rare autosomal trisomies, copy number variants and single-gene conditions, and this gradient is driven more by target prevalence and by placental biology than by sequencing chemistry. Second, DNA methylation currently functions far more securely as an analytical instrument, supporting fractional quantification and tissue-of-origin deconvolution, than as a validated diagnostic target for fetal disease, and the developmental literature that motivates epigenetic prediction rests overwhelmingly on postnatal tissues rather than on prenatal plasma. Third, paediatric evidence is the weakest link in the chain: prenatal detection demonstrably alters the ascertainment and the age distribution of childhood diagnoses, but longitudinal outcome data for prenatally ascertained children remain scarce. Priorities include phenotype-linked birth cohorts of prenatally screened pregnancies, prospective validation of methylation-based classifiers against paediatric endpoints, and evaluation frameworks that treat placental discordance as clinical information rather than analytical noise.